Cancer immunotherapy via targeted TGF-β signalling blockade in T_H cells.

ABSTRACT: Cancer arises from malignant cells that exist in dynamic multilevel interactions with the host tissue. Cancer therapies aiming to directly kill cancer cells, including oncogene-targeted therapy and immune-checkpoint therapy that revives tumour-reactive cytotoxic T lymphocytes, are effective in some patients^1,2, but acquired resistance frequently develops^3,4. An alternative therapeutic strategy aims to rectify the host tissue pathology, including abnormalities in the vasculature that foster cancer progression^5,6; however, neutralization of proangiogenic factors such as vascular endothelial growth factor A (VEGFA) has had limited clinical benefits^7,8. Here, following the finding that transforming growth factor-β (TGF-β) suppresses T helper 2 (T

SUBMITTER: Li S 

PROVIDER: S-EPMC8353603 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature